Silvia Silva-Duluc, MD
Psychiatry · Miami, FLNPI 1548291834
Payments from drug & device makers
Across 2,022 payments — averaging $5771.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2.9M
- Sumitomo Pharma America, Inc.$2.5M
- Teva Pharmaceuticals USA, Inc.$2.4M
- E.r. Squibb & Sons, L.L.C.$1.9M
- AbbVie$780K
- Corium, LLC$300K
- plus $860K from 24 others
Across 11 payments — averaging $4245.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$47K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 843 | $2,908,299 |
| Sumitomo Pharma America, Inc. | 121 | $2,467,805 |
| Teva Pharmaceuticals USA, Inc. | 540 | $2,410,823 |
| E.r. Squibb & Sons, L.L.C. | 19 | $1,944,610 |
| AbbVie(2 entities) | 100 | $779,538 |
| Corium, LLC | 22 | $299,864 |
| Sunovion Pharmaceuticals Inc. | 33 | $224,105 |
| Biohaven Pharmaceutical Holding Company Ltd. | 33 | $200,083 |
| Biohaven Pharmaceuticals, Inc. | 7 | $116,135 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $113,827 |
| Sage Therapeutics, LLC | 11 | $98,838 |
| Pfizer | 23 | $59,946 |
| Collegium Pharmaceutical, Inc. | 8 | $40,927 |
| Otsuka America Pharmaceutical, Inc. | 54 | $1,332 |
| Alkermes, Inc. | 45 | $1,099 |
| Neurocrine Biosciences, Inc. | 47 | $964 |
| Axsome Therapeutics, Inc. | 21 | $592 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $498 |
| Vanda Pharmaceuticals Inc. | 16 | $303 |
| Eisai Inc. | 4 | $261 |
| Lundbeck LLC | 11 | $261 |
| Johnson & Johnson | 12 | $251 |
| Almatica Pharma LLC | 9 | $164 |
| Tris Pharma Inc | 5 | $105 |
| Merck | 5 | $101 |
| Idorsia Pharmaceuticals US Inc | 4 | $69 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
| Neuronetics, Inc. | 1 | $17 |
| Bausch Health US, LLC | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $14 |
How this compares
$11,670,870 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Miami
- Patricia JunqueraMiami$10.8M
- Evelio SosaMiami$6.9M
- Mario CuervoMiami$6.7M
- Emelina ArochaMiami$4.9M
- Maria RodilMiami$4.5M
- Marc AgroninMiami$4M
- Nancy Navarro-GonzalezMiami$2.6M
- Francisco RicartMiami$2.6M
- Durim BozhdarajMiami$2.4M
- Carlos DangerMiami$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.